The head of the industry advocacy group talked about new priorities for the industry in light of the COVID-19 crisis, his thoughts on how the government and industry have responded, and what his group is doing to help companies cope with the financial burdens they may be facing.
Scott Whitaker, president and CEO of AdvaMed, recently sat down with Medtech Insight to talk about how the largest medical device industry group is shifting its priorities to tackle the ongoing COVID-19 crisis. While his organization has had to shift the way they operate, they are still working to represent industry’s interests with a focus on helping companies weather the pandemic.
Listen to our full interview in the player below.
The US FDA has announced classifications for five device types, including four diagnostics as well as a hand cream to protect healthcare workers exposed to radiation. Two of the products are newborn screening tests.
Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.
Medtronic is teaming up with IRCAD North America to build high-tech training and education experiences for surgeons and medical professionals in cardiovascular, neuroscience, and minimally invasive surgical specialties. The move could also further position Medtronic to seize on the growing robotics
Clairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.
Healthcare product industries await publication of the NHS 10-Year Plan, due out the coming days, which will focus on health generally not just the NHS, UK health secretary Wes Streeting said during a final prelaunch event on 24 June.
From June 30, new European Commission rules will attempt to redress an imbalance in medtech trade between the EU and the People’s Republic of China.
Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.
